Literature DB >> 27325930

Roles of ghrelin in left-ventricular remodelling after acute myocardial infarction.

Hideyuki Kondo1, Yukihiro Hojo1, Nozomu Takahashi1, Tomokazu Ikemoto1, Hirotaka Aoki1, Katsuya Dezaki2, Kazuomi Kario1, Takaaki Katsuki1, Toshihiko Yada2, Kazuyuki Shimada1.   

Abstract

OBJECTIVE: The purpose of this study was to elucidate the role of ghrelin after acute myocardial infarction (AMI) in left ventricular (LV) remodelling.
DESIGN: Prospective observational study.
SETTING: Jichi Medical University Hospital. PATIENTS: Fifty consecutive patients experiencing their first AMI.
INTERVENTIONS: Ghrelin was measured on the day of admission, day 7, day 14 and 6 months after AMI. Patients were treated by percutaneous coronary intervention, and successful myocardial reperfusion was accomplished within 12 h after onset. To analyse LV remodelling, the authors performed left ventriculographies on the day of admission and 6 months after AMI. MAIN OUTCOME MEASURES: Changes in LV volume.
RESULTS: Plasma ghrelin increased significantly after AMI (admission: 40.9±7.3; day 7: 89.5±11.0; day 14: 92.6±11.8 fmol/ml, p<0.0001). There was a significant correlation between ghrelin on day 14 and changes in LV volume over 6 months (r=+0.46, p<0.001). Multivariate regression analysis showed that ghrelin on day 14 is a significant predictor of LV remodelling after AMI (β=+0.44, p=0.001).
CONCLUSION: To our knowledge, this is the first report that shows a relation between circulating ghrelin after AMI and the progression of LV remodelling in the chronic phase. The elevation of ghrelin after AMI might be a compensatory mechanism to attenuate LV remodelling.

Entities:  

Keywords:  AMI; Acute coronary syndrome; Acute coronary syndromes; BMI; C-reactive protein; CPK-AUC; CRP; GH; Ghrelin; IGF-1; LV; LVEDVI; LVEF; Metabolism; Myocardial ischaemia; PCI; Ventricular remodelling; acute myocardial infarction; body mass index; creatine phosphokinase-area under the curve; growth hormone; insulin-like growth factor-1; left ventricular; left ventricular ejection fraction; left ventricular end-diastolic volume index; percutaneous coronary intervention

Year:  2010        PMID: 27325930      PMCID: PMC4898497          DOI: 10.1136/ha.2009.000927

Source DB:  PubMed          Journal:  Heart Asia        ISSN: 1759-1104


  26 in total

Review 1.  Postinfarction left ventricular remodelling: where are the theories and trials leading us?

Authors:  Z R Yousef; S R Redwood; M S Marber
Journal:  Heart       Date:  2000-01       Impact factor: 5.994

2.  Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting.

Authors:  S D Anker; A L Clark; M Kemp; C Salsbury; M M Teixeira; P G Hellewell; A J Coats
Journal:  J Am Coll Cardiol       Date:  1997-10       Impact factor: 24.094

3.  World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  1997-03-19       Impact factor: 56.272

4.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors:  B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

5.  Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure.

Authors:  Noritoshi Nagaya; Junji Moriya; Yoshio Yasumura; Masaaki Uematsu; Fumiaki Ono; Wataru Shimizu; Kazuyuki Ueno; Masafumi Kitakaze; Kunio Miyatake; Kenji Kangawa
Journal:  Circulation       Date:  2004-11-29       Impact factor: 29.690

6.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

7.  Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding behavior, and sleep-wake patterns in rats.

Authors:  Virginie Tolle; Marie-Helene Bassant; Philippe Zizzari; Frederique Poindessous-Jazat; Catherine Tomasetto; Jacques Epelbaum; Marie-Therese Bluet-Pajot
Journal:  Endocrinology       Date:  2002-04       Impact factor: 4.736

Review 8.  Reperfusion in acute myocardial infarction: effect of timing and modulating factors in experimental models.

Authors:  K A Reimer; R S Vander Heide; V J Richard
Journal:  Am J Cardiol       Date:  1993-12-16       Impact factor: 2.778

9.  Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.

Authors:  John K Ninomiya; Gilbert L'Italien; Michael H Criqui; Joanna L Whyte; Anthony Gamst; Roland S Chen
Journal:  Circulation       Date:  2003-12-15       Impact factor: 29.690

10.  Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT.

Authors:  Gianluca Baldanzi; Nicoletta Filigheddu; Santina Cutrupi; Filomena Catapano; Sara Bonissoni; Alberto Fubini; Daniela Malan; Germano Baj; Riccarda Granata; Fabio Broglio; Mauro Papotti; Nicola Surico; Federico Bussolino; Jorgen Isgaard; Romano Deghenghi; Fabiola Sinigaglia; Maria Prat; Giampiero Muccioli; Ezio Ghigo; Andrea Graziani
Journal:  J Cell Biol       Date:  2002-12-16       Impact factor: 10.539

View more
  1 in total

Review 1.  Heal the heart through gut (hormone) ghrelin: a potential player to combat heart failure.

Authors:  Shreyasi Gupta; Arkadeep Mitra
Journal:  Heart Fail Rev       Date:  2020-10-06       Impact factor: 4.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.